Metformin mitigates carbon tetrachloride-induced TGF-β1/Smad3 signaling and liver fibrosis in mice
Authors:
- 1 June 2017
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 90, 421-426
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Evidence-based clinical practice guidelines for liver cirrhosis 2015Journal of Gastroenterology, 2016
- TGF‐β signalling and liver diseaseThe FEBS Journal, 2016
- Crucial steps towards an effective treatmentNature Reviews Gastroenterology & Hepatology, 2016
- Metformin and Inflammation: Its Potential Beyond Glucose-lowering EffectEndocrine, Metabolic & Immune Disorders - Drug Targets, 2015
- Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the EndotheliumMedical Principles and Practice, 2015
- Novel insights into the function and dynamics of extracellular matrix in liver fibrosisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2015
- Metformin, an Old Drug, Brings a New Era to Cancer TherapyThe Cancer Journal, 2015
- Metformin: From Mechanisms of Action to TherapiesCell Metabolism, 2014
- Molecular mechanism of action of metformin: old or new insights?Diabetologia, 2013
- Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS–Mediated SignalingDiabetes, 2008